Paulsson Janna, Ehnman Monika, Östman Arne
Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
Future Oncol. 2014;10(9):1695-708. doi: 10.2217/fon.14.83.
PDGF receptors (PDGFRs) exert cell type-specific effects in many different tumor types. They are emerging as key regulators of mesenchymal cells of the tumor microenvironment, and of many common malignancies, such as cancer of the breast, colon and prostate. In some tumor types PDGFRs are genetically activated and are thus directly involved in stimulation of malignant cell growth. Recent studies have uncovered clinically relevant variations in stromal PDGFR expression. High stromal PDGFRβ expression or activation is associated with poor prognosis in breast and prostate cancer. Indications of prognostic significance of stromal PDGFRβ expression in various GI tract tumor types also exist. The prognostic significance of PDGFRα and β in malignant cells of common epithelial tumor types should be further studied. Collectively data suggest that continued characterization of PDGFR expression in human tumors should present opportunities for improved accuracy in prognosis and also allow novel biomarker-based clinical studies exploring the efficacy of PDGFR-directed tumor therapies.
血小板衍生生长因子受体(PDGFRs)在多种不同肿瘤类型中发挥细胞类型特异性作用。它们正成为肿瘤微环境中间充质细胞以及许多常见恶性肿瘤(如乳腺癌、结肠癌和前列腺癌)的关键调节因子。在某些肿瘤类型中,PDGFRs发生基因激活,从而直接参与刺激恶性细胞生长。最近的研究发现了基质PDGFR表达的临床相关差异。基质PDGFRβ高表达或激活与乳腺癌和前列腺癌的不良预后相关。在各种胃肠道肿瘤类型中也存在基质PDGFRβ表达具有预后意义的迹象。PDGFRα和β在常见上皮肿瘤类型的恶性细胞中的预后意义应进一步研究。总体数据表明,持续表征人类肿瘤中的PDGFR表达应为提高预后准确性提供机会,也有助于开展基于新型生物标志物的临床研究,探索PDGFR导向肿瘤治疗的疗效。